Durvalumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, non-randomized, phase-2 clinical trial.

Shuchi Gulati,McKenzie Crist,Muhammed Kashif Riaz,Vinita Takiar,Maria Lehn,Ilaina Monroe,Sarah Palackdharry,Nicky Kurtzweil,Roman Jandarov,Nusrat Harun,Trisha M Wise-Draper

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 1|浏览10

暂无评分

摘要

The combination of cetuximab and durvalumab demonstrated durable activity with a tolerable safety profile in metastatic HNSCC and warrants further investigation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要